Ascendis Pharma A/S is a commercial-stage biopharmaceutical company that focuses on developing and commercializing therapies for rare endocrine diseases. The company's core innovation is its proprietary TransCon (Transient Conjugation) technology platform, which temporarily links a therapeutic molecule to a carrier to enable the predictable, sustained release of proteins, peptides, or small molecules in the body. This approach aims to optimize efficacy, reduce dosing frequency, and improve patient compliance compared to traditional treatments.
Ascendis Pharma's commercial portfolio is driven by two primary products. SKYTROFA (lonapegsomatropin) is a once-weekly treatment for pediatric and adult growth hormone deficiency. YORVIPATH (palopegteriparatide) is a treatment for adult hypoparathyroidism. The company is also advancing a clinical pipeline that includes TransCon CNP for achondroplasia.
In 2025, Ascendis Pharma generated approximately €720 million in total revenue. The majority of its revenue is derived from commercial product sales, with YORVIPATH contributing approximately €477 million and SKYTROFA contributing €206 million. The company also generates non-product revenue through strategic licensing agreements and partnerships, such as its collaborations with Novo Nordisk and Teijin, as well as its stake in VISEN Pharmaceuticals for the Greater China market. Headquartered in Denmark, Ascendis Pharma maintains a significant global footprint with operations and commercial infrastructure across Europe and the United States.
